Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Intrexon Ties up with External Investors for Type I Diabetes

Intrexon Corporation XON announced that it has entered into exclusive channel collaboration with external investors led by White Rock Capital Partners, to form Intrexon T1D Partners, LLC, in order to develop antigen-specific immunotherapy using its ActoBiotics platform, for the treatment of type I diabetes (T1D) in humans.

Per the agreement, Intrexon received $10 million as technology access fees and will own 50% of interest in the joint venture. The company will also be responsible for all costs related to the development, manufacture, approval and commercialization of the product.

The company stated that the objective of the program is to create an easy-to-take pill for people suffering from T1D to halt autoimmune-induced damage, both for early-stage patients before they become insulin dependent, and in certain advanced-stage patients for the potential prevention of the requirement for external administration of insulin.

According to information provided by the company, approximately 1.25 million individuals are affected by T1D in the U.S. This market is anticipated to expand to an estimated $13.6 billion by 2023.

We remind investors that Intrexon has been pursuing strategic collaborations in the past in order to develop its pipeline candidates. Earlier this year, the company has entered into a collaboration agreement with Fibrocell Science, Inc., FCSC for the development of genetically modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions.

Intrexon currently has a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector are AMAG Pharmaceuticals, Inc. AMAG and Emergent BioSolutions, Inc. EBS,  both sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
 
FIBROCELL SCIEN (FCSC): Free Stock Analysis Report
 
EMERGENT BIOSOL (EBS): Free Stock Analysis Report
 
INTREXON CORP (XON): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research